Video originally created by FDA -- posted by Lawsuit.com on August 27, 2008
Lawsuit.com: Avandia and Diabetic Emacular Edema -- the potential risks associated with taking Avandia are discussed by the FDA.
Glaxo SmithKline has notified health professionals about reports of diabetic macular edema in patients receiving Avandia (rosiglitazone maleate) which is used to treat type 2 diabetes. These reports involved both new cases of macular edema and worsening of existing cases. In the majority of instances, patients also reported concurrent peripheral edema. In some cases, the macular edema resolved or improved when the drug was discontinued, and in one case it resolved after the dose was reduced.
Video originally created by FDA -- posted by Lawsuit.com on March 18, 2008
The manufacturers of thiazolidinedione drugs have strengthened warnings about the risks of heart failure with these medications, which are use to treat type 2 diabetes. They are sold as Avandia (rosiglitazone maleate), Avandaryl (rosiglitazone maleate and glimepiride), and Avandamet (rosiglitazone maleate and metformin hydrochloride), which all contain rosiglitazone, and Actos (pioglitazone hydrochloride), Duetact (pioglitazone hydrochloride and glimepride) and Actoplus met, which all contain pioglitazone.
The drug labels already had information about heart failure risk, but now there is a new boxed warning that re-emphasizes that these drugs may cause or worsen heart failure in certain patients, and stresses the importance of carefully monitoring patients for signs of heart failure.
The labeling recommends that after starting thiazolidinedione therapy or increasing the dose, patients should be observed carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema. If any of these signs and symptoms develop and heart failure is confirmed, practitioners should start appropriate management of the heart failure and consider stopping or reducing the dose of the drug. The boxed warning also notes that these drugs are not recommended for patients with symptomatic heart failure, and are specifically contraindicated in patients with NYHA Class III or IV heart failure.
